In some markets, the time it takes to reimburse a new medicine can cause significant delays for patients to access these new therapies. UCB is working to reduce the time it takes for UCB medicines to complete these access processes faster than the industry average in an effort to ensure patients have access to our solutions in a timely manner. In countries like the U.S., we support policies that encourage timely review and access to new medicines for patients and oppose to policies that could slow down patient access.
IQVIA, a world leader in data, technology and advanced analytics in healthcare, calculated the average time taken by the industry to complete these reimbursement steps, building on their work undertaken with EFPIA (European Federation of Pharmaceutical Industries and Associations) in their WAIT study (EFPIA Patients W.A.I.T. Indicator 2019 Survey, 2020 IQVIA). UCB worked with IQVIA to expand this analysis to cover all the countries where UCB operates, to establish a benchmark which UCB will strive to outperform. UCB also commits to updating this metric every year, as we know that the access environment is constantly shifting.